Skip to main content

Table 2 Clinical characteristics according to PDGF group

From: Platelet-derived growth factor predicts prolonged relapse-free period in multiple sclerosis

  n PDGF group p
Absent Medium High
38 29 33
Diagnosis, CIS n (%) 11 (28.9%) 11 (37.9%) 9 (27.3%) 0.625
Diagnosis, RR n (%) 27 (71.1%) 18 (62.1%) 24 (72.7%)
Age Mean (SD) 33.4 (9.38) 32.3 (8.98) 35.2 (11.82) 0.625a
Sex, F n (%) 29 (76.3%) 18 (62.1%) 23 (69.7%) 0.458
Disease duration, months Median (IQR) 8 (1.7–18.3) 7 (1–34) 12 (3–84) 0.218b
Disease activity at diagnosis
 No activity n (%) 16 (42.1%) 11 (37.9%) 15 (45.5%) 0.817
 Clinical relapse and/or Gd+ MRI n (%) 22 (61.1%) 18 (62.1%) 18 (54.5%)
Escalation to second line n (%) 8 (21.1%) 7 (24.1%) 4 (12.1%) 0.446
EDSS at baseline Median (IQR) 2 (1–2) 1.5 (1–2) 2 (1–2) 0.998
  1. All p values refer to chi-square test
  2. aAnova test
  3. bKruskal–Wallis test